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We thank Dominguez-Rodriguez & Abreu-Gonzalez1 for their comment on our ESC Working 
Group (WG) Position Paper on cardioprotection2, in which they propose melatonin to be a 
promising cardioprotective strategy. This was based, in part, on the recently published results 
of the MARIA trial, in which they investigated the cardioprotective effects of melatonin in ST-
segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous 
coronary intervention (PPCI)3. However, in the MARIA trial, the authors found that intravenous 
and intracoronary melatonin administered at the time of reperfusion failed to reduce acute 
myocardial infarct (MI) size (assessed by cardiac MRI)3. In fact, in that study, melatonin was 
found to actually worsen adverse post-MI left ventricular (LV) remodelling when compared to 
placebo (with significantly higher left LV end diastolic and systolic volumes, and lower ejection 
fraction on cardiac MRI at 4 months following PPCI)3. The cause of this detrimental effect of 
melatonin on post-MI LV remodelling is not clear, but may be related to its reported effects on 
increasing myocardial accumulation of collagen and glycosaminoglycans following infarction4. 
In another study, oral melatonin started on the night following PPCI and continued daily during 
the hospitalisation, had mixed results on enzymatic MI size following STEMI (CK-MB and hs-
Troponin-T at 6 hours post-PPCI)5, although the study was underpowered (only 40 patients), 
and the dosing regimen was suboptimal. Another clinical study reported cardioprotective 
effects with 5 days’ pre-treatment with melatonin in patients undergoing coronary artery 
bypass graft (CABG) surgery, as evidenced by less peri-operative myocardial injury when 
compared to placebo pre-treatment6, suggesting that melatonin may be more effective as a 
cardioprotective agent when administered prior to index ischaemia (as in CABG surgery) 
rather than at the time of reperfusion (as in STEMI patients). 
 The neutral findings of the MARIA trial on a background of promising experimental 
data with melatonin, underscores the challenges in translating novel cardioprotective 
therapies from the bench to the bedside, as highlighted in our ESC WG Position paper2. It is 
important to note that the experimental animal data showing beneficial effects with melatonin 
on MI size were largely restricted to small animal MI models with no comorbidities and 
comedications7, and most of these experimental studies had examined the long-terms effects 
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of melatonin on post-MI adverse remodelling. Of note, in a clinically relevant large animal 
closed-chest reperfused porcine MI model, it was reported that intravenous and intracoronary 
melatonin administered prior to reperfusion failed to reduce MI size8, suggesting inconsistent 
cardioprotection with melatonin even in the experimental setting. These studies highlight the 
importance of thoroughly testing novel cardioprotective therapies in the laboratory setting, 
before proceeding with clinical cardioprotection studies9.  
 In a post-hoc subgroup analysis of the MARIA trial, Dominguez-Rodriguez & Abreu-
Gonzalez1 found that melatonin reduced MI size in STEMI patients presenting within 2.5 hours 
of chest pain onset (although these results have been published so far only as an abstract)10, 
a finding which is consistent with studies showing beneficial effects with cardioprotective 
therapies, such as adenosine and exenatide, administered to patients presenting with short 
ischaemic times (<3 hours)11-13 - whether the detrimental effects of melatonin on post-MI LV 
remodelling observed in the MARIA study were also observed in this subgroup analysis was 
not reported. Moreover, in patients presenting with ischaemic times of >3.5 hours, melatonin 
actually increased MI size when compared to placebo, suggesting a detrimental effect of 
melatonin in these patients10. 
 In summary, the aim of our ESC WG Position Paper on cardioprotection had been to 
review the current status of cardioprotection, highlight promising new cardioprotective targets 
and therapies, and unfortunately, the current clinical evidence does not appear to support 
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